Central vascular access in kidney and cancer care: devices, biomaterial strategies, and prevention of complications
Rattachement africain : es, be. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Chronic kidney disease (CKD) and cancer are among the most prevalent chronic conditions that increasingly demand reliable long-term central venous access devices (CVADs), including central venous catheters (CVCs), peripherally inserted central catheters (PICCs), and implantable ports (PORTs). Despite their essential role, CVAD-related complications, primarily infections and thrombosis, continue to compromise patient safety and burden healthcare systems, remaining a major challenge. Beyond patient- and procedure-related factors, device-intrinsic characteristics such as material composition, surface properties, and design features critically determine thrombogenicity, infection risk, and overall performance. This review provides recent advances in CVAD biomaterials, emphasizing surface engineering strategies aimed at antimicrobial activity, antithrombogenicity, and multifunctional performance. Antimicrobial coatings, antithrombogenic surfaces, and novel polymeric designs demonstrate promising potential to mitigate infection and thrombotic events. However, most innovations are currently unfunctional or lack long-term clinical validation, and their translation into practice is constrained by challenges in standardization, durability, and multifunctional integration. CKD and cancer populations are presented as case studies to illustrate how targeted biomaterial design and engineering can optimize device outcomes. Finally, we discuss future perspectives, emphasizing the need for interdisciplinary biomaterials research combining materials science, engineering, and clinical expertise to develop durable, multifunctional CVAD surfaces that enhance safety, extend device longevity, and reduce the healthcare burden associated with long-term vascular access in high-risk patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Central vascular access in kidney and cancer care: devices, biomaterial strategies, and prevention of complications
- Date Crossref
- 10/09/2026
- Éditeur
- F1000 Research Ltd
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Hospital Terrassa pays non établi dans la noticeÉtablissement de santé
-
University of Liège pays non établi dans la noticeUniversité ou école supérieure
-
Centre Hospitalier Universitaire de Liège pays non établi dans la noticeÉtablissement de santé
-
FRESCI Terrassa Catalonia 08233 SCIENCE&STRATEGY SL pays non établi dans la noticeInstitution
-
Liège Walloon Region CM4Cure SA pays non établi dans la noticeEntreprise
-
Cardiology Department Liège Walloon Region CHU de Liège - Hopital du Sart Tilman Cardiologie pays non établi dans la noticeÉtablissement de santé
Hospital Terrassa, University of Liège et Centre Hospitalier Universitaire de Liège, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.